Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis

Tumor necrosis factor-α inhibitors may induce various cutaneous side effects including eczematous-like lesions. The management of such side effects can be challenging. Herein, we report a case of a 55-year-old man who had a flare-up and subsequent improvement of atopic dermatitis during treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yayli, Savas, Irla, Nathalie, Yawalkar, Nikhil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Published online: November, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861871/
https://www.ncbi.nlm.nih.gov/pubmed/24348383
http://dx.doi.org/10.1159/000356776
_version_ 1782295693918994432
author Yayli, Savas
Irla, Nathalie
Yawalkar, Nikhil
author_facet Yayli, Savas
Irla, Nathalie
Yawalkar, Nikhil
author_sort Yayli, Savas
collection PubMed
description Tumor necrosis factor-α inhibitors may induce various cutaneous side effects including eczematous-like lesions. The management of such side effects can be challenging. Herein, we report a case of a 55-year-old man who had a flare-up and subsequent improvement of atopic dermatitis during treatment of severe psoriasis with adalimumab.
format Online
Article
Text
id pubmed-3861871
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-38618712013-12-13 Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis Yayli, Savas Irla, Nathalie Yawalkar, Nikhil Case Rep Dermatol Published online: November, 2013 Tumor necrosis factor-α inhibitors may induce various cutaneous side effects including eczematous-like lesions. The management of such side effects can be challenging. Herein, we report a case of a 55-year-old man who had a flare-up and subsequent improvement of atopic dermatitis during treatment of severe psoriasis with adalimumab. S. Karger AG 2013-11-14 /pmc/articles/PMC3861871/ /pubmed/24348383 http://dx.doi.org/10.1159/000356776 Text en Copyright © 2013 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: November, 2013
Yayli, Savas
Irla, Nathalie
Yawalkar, Nikhil
Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
title Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
title_full Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
title_fullStr Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
title_full_unstemmed Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
title_short Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
title_sort adalimumab in recalcitrant severe psoriasis associated with atopic dermatitis
topic Published online: November, 2013
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861871/
https://www.ncbi.nlm.nih.gov/pubmed/24348383
http://dx.doi.org/10.1159/000356776
work_keys_str_mv AT yaylisavas adalimumabinrecalcitrantseverepsoriasisassociatedwithatopicdermatitis
AT irlanathalie adalimumabinrecalcitrantseverepsoriasisassociatedwithatopicdermatitis
AT yawalkarnikhil adalimumabinrecalcitrantseverepsoriasisassociatedwithatopicdermatitis

Ejemplares similares